Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
  • TickerALGFT
  • ISINFR0004163111
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Jean-Jacques Le Fur

GENFIT: The success story continues | BUY | EUR65

GENFIT - BUY | EUR65(+189%) The success story continues Successful IPO on NASDAQ: EUR155m raised Some adjustments to our model without change in our FV Elafibranor well positioned in the NASH race Positive results in PBC

Jean-Jacques Le Fur

GENFIT: The success story continues | BUY | EUR65

GENFIT - BUY | EUR65(+189%) The success story continues Successful IPO on NASDAQ: EUR155m raised Some adjustments to our model without change in our FV Elafibranor well positioned in the NASH race Positive results in PBC

Martial Descoutures ...
  • Pierre Corby

Genfit : EASL 2019: Elafibranor, potential best-in-class in NASH and PBC

>Feedback from EASL 2019: in NASH, Intercept disappoints - Last week we were in Vienna for the ILC (International Liver Congress) and EASL (European Association for the Study of the Liver) with all of the companies that are currently developing treatment for conditions affecting the liver. With regards to NASH, there was no breakthrough even though it is a pivotal year with the publication of the first results of phase III testing for the main players. We already knew...

Martial Descoutures ...
  • Pierre Corby

Genfit : EASL 2019 : Elafibranor, best-in-class dans la NASH et la PBC ?

>Feedback EASL 2019 : dans la NASH, Intercept déçoit - Nous étions la semaine dernière à Vienne pour le congrès ILC (International Liver Congress) de l’EASL (European Association for the Study of the Liver) en présence de toutes les sociétés développant des traitements contre les maladies du foie. Concernant la NASH, il n’y a pas eu de révélation breakthrough cette année, bien qu’il s’agisse d’une année charnière avec la publication des premiers résultats de phase 3 d...

Martial Descoutures ...
  • Pierre Corby

Genfit : IPO launched in the US

>IPO launched in the US (Nasdaq) - Genfit yesterday evening announced the start of the IPO process in the US with the filing of an F-1 with the Securities and Exchange Commission (SEC). This listing will be in the usual form of American Depositary Shares (ADS), each representing one ordinary share. Alongside this IPO in the US market (Nasdaq), Genfit is looking to carry out an issue of ordinary shares through a private placement in Europe. The terms of the offer have ...

Martial Descoutures ...
  • Pierre Corby

Genfit : L’IPO US est lancée

>Lancement de l’IPO aux USA (Nasdaq) - Genfit a annoncé hier soir le démarrage du processus IPO aux USA via le dépôt d’un Document d’Enregistrement Form F-1 auprès de la Securities and Exchange Commission (SEC). Cette introduction en bourse se fera classiquement sous la forme d’American Depositary Shares (ADS) représentant chacune une action ordinaire. En même temps que cette IPO sur le marché américain (Nasdaq), Genfit souhaite réaliser une émission d’actions ordinai...

A director bought 83,333 shares at 22.200EUR and

A director at Genfit bought 83,333 shares at 22.200EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

Christophe Chaput ...
  • Hela Zarrouk
  • Jeremy Garnier
  • Martial Descoutures
  • Nicolas Thorez
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 04/15/2019

...

Christophe Chaput ...
  • Hela Zarrouk
  • Jeremy Garnier
  • Martial Descoutures
  • Nicolas Thorez
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 15/04/2019

...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Corby
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 02/28/2019

...

Aurelien Sivignon ...
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jerôme Bodin
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Corby
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 28/02/2019

...

Benoit Valleaux ...
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Jean-François Granjon
  • Martial Descoutures
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 02/12/2019

...

Thanks to a better fundamental star rating, GENFIT sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to GENFIT (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 19, 2019, the closing price was EUR 20.54 and its expected value was estimated at EUR 18.45.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Genfit - Assemblée générale des actionnaires du 13 juin 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Jehanne Leroy

Proxy Report - 15/06/2018

Alors même que la société recueillait l’an dernier des taux d’approbation assez faibles sur ses autorisations financières, principalement en raison de leur maintien en période d’offre publique, elle réitère cette année, sourde à la contestation de ses actionnaires. Ainsi, comme l’année dernière, Proxinvest ne soutiendra pas ces autorisations, non seulement en raison du maintien en période d’offre publique, mais également en raison des montants demandés dans le cas des autorisations sans DPS. De la même façon, alors que la plupart des sociétés du SBF120 proposent des rémunérations sous forme d...

Matthieu DRIOL

Short term view - GENFIT : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €21.90. The next target is at €17.80, then €16.50. Passing €28.28 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - GENFIT : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 21,90 € prochainement. Le prochain objectif est à 17,80 €, puis 16,50 €. Le franchissement de 28,28 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - GENFIT : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €17.80. The background trend would be questioned should prices rise above €28.28.

Matthieu DRIOL

Analyse court terme - GENFIT : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 17,80 €. La tendance de fond serait remise en cause en cas de franchissement de 28,28 €.

Matthieu DRIOL

Medium term view - GENFIT : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €16.30, then €6.74. Passing €35.59 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch